Most cited papers from Radiotherapiegroep

Radiotherapiegroep

What are the most cited papers from Radiotherapiegroep?

The most cited paper from Radiotherapiegroep is "Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial" (Mila Donker et al., 2014), with 1,891 citations. Next come "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial" (1,786) and "Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial" (1,154).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 73 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Mila Donker et al. · The Lancet Oncology Open access	15 Oct 2014	1,891
2	Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial Carien L. Creutzberg, Wim LJ van Putten, Peter C.M. Koper et al. · The Lancet	Apr 2000	1,786
3	Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Remi A. Nout, VTHBM Smit, Hein Putter et al. · The Lancet	Mar 2010	1,154
4	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer Ben J. Slotman, Corinne Faivre Finn, Gijs W.P.M. Kramer et al. · New England Journal of Medicine Open access	15 Aug 2007	1,138
5	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts Ellen Stelloo, Remi A. Nout, Elisabeth M. Osse et al. · Clinical Cancer Research	22 Mar 2016	872
6	The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5 Kasper M. A. Rouschop, Twan van den Beucken, Ludwig Jerome Dubois et al. · Journal of Clinical Investigation Open access	28 Dec 2009	821
7	Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer Jan P. van Meerbeeck, Gijs W.P.M. Kramer, Paul E. Van Schil et al. · JNCI Journal of the National Cancer Institute Open access	20 Mar 2007	713
8	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study Richard Pötter et al. · The Lancet Oncology Open access	29 Mar 2021	666
9	Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials Vera Oppedijk, Ate van der Gaast, J. Jan B. van Lanschot et al. · Journal of Clinical Oncology	14 Jan 2014	515
10	Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial Marjolein Y.V. Homs, Ewout Willem Steyerberg, Wilhelmina M.H. Eijkenboom et al. · The Lancet	Oct 2004	510
11	Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial Luca Incrocci, Ruud C. Wortel, Wendimagegn Ghidey Alemayehu et al. · The Lancet Oncology	21 Jun 2016	483
12	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials Tjalling Bosse, Elke E.M. Peters, Carien L. Creutzberg et al. · European Journal of Cancer Open access	6 Jun 2015	453
13	Prediction of survival in patients with metastases in the spinal column Yvette M. van der Linden, P. D. S. Dijkstra, Ernest J. A. Vonk et al. · Cancer Open access	8 Dec 2004	403
14	Survival after relapse in patients with endometrial cancer: results from a randomized trial☆ Carien L. Creutzberg, Wim L.J. van Putten, Peter C.M. Koper et al. · Gynecologic Oncology	25 Apr 2003	376
15	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology Open access	8 Mar 2016	319
16	Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study) Maarten C.C.M. Hulshof, Elisabeth D. Geijsen, Tom Rozema et al. · Journal of Clinical Oncology Open access	8 Jun 2021	316
17	Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis Roel J.H.M. Steenbakkers, Joop C. Duppen, Isabelle Fitton et al. · International Journal of Radiation OncologyBiologyPhysics	29 Sep 2005	309
18	Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial Philip M. Poortmans et al. · The Lancet Oncology Open access	2 Nov 2020	302
19	Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial Edward Chow, Yvette M. van der Linden, Daniel E. Roos et al. · The Lancet Oncology Open access	22 Dec 2013	299
20	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy for the PORTEC Study Group, Bastiaan G. Wortman, Carien L. Creutzberg et al. · British Journal of Cancer Open access	Oct 2018	291
21	Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where? Rick L. Haas, Thomas F. DeLaney, Brian P O'Sullivan et al. · International Journal of Radiation OncologyBiologyPhysics	19 Apr 2012	265
22	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer Anne Sophie V M van den Heerik et al. · International Journal of Gynecological Cancer Open access	12 Oct 2020	251
23	Long-Term Outcome and Quality of Life of Patients With Endometrial Carcinoma Treated With or Without Pelvic Radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) Trial Remi A. Nout, Lonneke V. van de Poll‐Franse, Marnix L.M. Lybeert et al. · Journal of Clinical Oncology Open access	29 Mar 2011	245
24	The morbidity of treatment for patients with stage I endometrial cancer: results from a randomized trial Carien L. Creutzberg, Wim L.J. van Putten, Peter C.M. Koper et al. · International Journal of Radiation OncologyBiologyPhysics	Dec 2001	194
25	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01) Cecile Le Pechoux, A. Laplanche, Corinne Faivre Finn et al. · Annals of Oncology Open access	8 Dec 2010	191
26	Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08) Lori M. van Roozendaal, Marissa L. G. Vane, Thijs van Dalen et al. · BMC Cancer Open access	Jul 2017	190
27	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology Open access	2 Feb 2015	186
28	Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas Karen J. Neelis, Erik C. Schimmel, Maarten H. Vermeer et al. · International Journal of Radiation OncologyBiologyPhysics	2 Oct 2008	174
29	Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial Bastiaan G. Wortman, Tjalling Bosse, Remi A. Nout et al. · Gynecologic Oncology Open access	3 Aug 2018	172
30	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data Remi A. Nout, Hein Putter, Ina Maria Jurgenliemk-Schulz et al. · European Journal of Cancer Open access	14 Dec 2011	168
31	Observer variation in target volume delineation of lung cancer related to radiation oncologist–computer interaction: A ‘Big Brother’ evaluation Roel J.H.M. Steenbakkers, Joop C. Duppen, Isabelle Fitton et al. · Radiotherapy and Oncology	27 Oct 2005	163
32	Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998) Ronald B. Keus, Remi A. Nout, Jean‐Yves Blay et al. · Annals of Oncology Open access	18 Jul 2013	138
33	Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts Sarah Fremond et al. · The Lancet Digital Health Open access	7 Dec 2022	136
34	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial Stephanie M. de Boer, Remi A. Nout, Ina Maria Jurgenliemk-Schulz et al. · International Journal of Radiation OncologyBiologyPhysics Open access	18 Aug 2015	126
35	Desmoid tumors: need for an individualized approach Eelco de Bree, Ronald B. Keus, John Melissas et al. · Expert Review of Anticancer Therapy	Apr 2009	120
36	First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma Anneke M. Westermann, Ellen Louise Jones, Baard‐Christian Schem et al. · Cancer Open access	20 Jun 2005	119
37	First experience with model-based selection of head and neck cancer patients for proton therapy Makbule Tambaş, Roel J.H.M. Steenbakkers, Hans Paul van der Laan et al. · Radiotherapy and Oncology Open access	5 Aug 2020	112
38	Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study Boon Hui Chua et al. · The Lancet Open access	Aug 2022	109
39	Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994 Gemma G. Kenter et al. · Journal of Clinical Oncology Open access	Sep 2023	106
40	Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer J. Knegjens, Michael Hauptmann, Frank A. Pameijer et al. · Head & Neck	13 Jul 2010	103
41	Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer Nanda Horeweg et al. · Journal of Clinical Oncology Open access	24 Jul 2023	101
42	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) Murat Gültekin et al. · Cancer Medicine Open access	18 Nov 2020	101
43	Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991 Oscar Matzinger, Frederic Duclos, A. van den Bergh et al. · European Journal of Cancer	13 Aug 2009	101
44	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series ofin vitrobreast cancer models Carol Ward, James R. Meehan, Peter Mullen et al. · Oncotarget Open access	3 Jul 2015	98
45	Engagement of I-Branching β-1, 6- N -Acetylglucosaminyltransferase 2 in Breast Cancer Metastasis and TGF-β Signaling Haijun Zhang, Fanyan Meng, Sherwin Wu et al. · Cancer Research Open access	13 Jul 2011	95
46	Functional characterization of the 19q12 amplicon in grade III breast cancers Rachael Natrajan, Alan G. Mackay, Paul M Wilkerson et al. · Breast Cancer Research Open access	20 Mar 2012	95
47	Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups Jean-François Bosset, Felicitas Roelofsen, David A.L. Morgan et al. · European Journal of Cancer Open access	28 Dec 2002	92
48	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer Nanda Horeweg, Marco de Bruyn, Remi A. Nout et al. · Cancer Immunology Research Open access	30 Sep 2020	91
49	Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study Monica F. Serban, Christian Kirisits, Astrid de Leeuw et al. · International Journal of Radiation OncologyBiologyPhysics	30 Jan 2020	90
50	Proteolytic Cleavage of Notch: “HIT and RUN” Geert van Tetering, Marc Vooijs · Current Molecular Medicine Open access	Jun 2011	90

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.